BlooDe : System for Primary Haemostasis Evaluation in Flow

CONTEXT

Appropriate anti-thrombotic medication to each patient needs, health disorders and their complications (art of drugs combination), appropriate evaluation of hemorrhage risk during surgery are few of the many reasons why accurate primary hemostasis evaluation is needed.

Current devices on the market lack accuracy and sensitivity and aren’t relevant according to clinicians.

DESCRIPTION

BlooDe is a new more sensitive and precise system that, amongst other things, make possible the adaptation of protocols to specific patient's hemostasis situation.

Completed developments:

-Functional prototype – TRL 6
-Clinical study based on whole blood of healthy donors and patient with severe von Willebrand Disease successfully completed

Current developments:

- On-going clinical study

- Successful and accurate detection of vWF deficiency and of antiplatelet drugs’effect.

Upcoming development:

-  Pre-industrial prototype launching

COMPETITIVE ADVANTAGES

Increased sensitivity

• Detection of mild bleeding disorders

Higher accuracy

• Diagnostic quality
• Monitor treatment / Avoid unnecessary treatment

Predictive value

• Reduce need for blood/platelet transfusion
• Reduce complications post-operatively
• Diminish days of hospitalization
• Save costs

MARKETS AND APPLICATIONS

Medical : Pre-operative assessment

• Medical collagen based Evaluation of Primary Haemostasis before surgery

Pharma : testing new drugs

• Analysis of blood flow for testing new drugs

DEVELOPMENT STAGE 

Prototype undergoing validation in a representative environment(TRL 5-6)

RESEARCH TEAM

FEMTO-ST Institute

Franche-Comté University  - CNRS

INTELLECTUAL PROPERTY

Code deposit

TARGET PARTNERSHIP

Co-development to orient the technology according to the needs of manufacturers

CONTACT

Abdelkader GUELLIL
Business Developpement Manager
+33 (0)6 26 61 89 06
abdelkader.guellil@sayens.fr